Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, will host the Competitive Landscape Seminar Series: Biologics and Biosimilars, a one-day seminar addressing current and future trends in the biologics and biosimilars markets on September 14, 2010. The seminar will include presentations on a range of industry and therapeutic-specific topics, and will help pharmaceutical companies understand market opportunities for biologics and biosimilars.

The seminar will be held in New York, N.Y. on September 14, 2010 and will answer the following questions:

  --  Who are the key players in the biologics market and who will see the       greatest growth?   --  Which companies are in the best position to produce biosimilars?   --  How quickly will biologics saturate niche markets?   --  What are the current and future prospects for biologics in the       emerging markets?   --  How are payers influencing the biologics market in the United States?   --  What opportunities and challenges lie ahead for agents in specific       therapeutic areas such as immune and oncology?  

"Developments in the biologics and biosimilars markets are constantly evolving and present significant opportunities, as well as potential challenges, for pharmaceutical manufacturers," said Decision Resources Chief Operating Officer Jason LaBonte. "This high-value seminar is geared toward both manufacturers already operating in the biologics and biosimilars markets, as well as companies exploring market opportunities in this space. Attendees will leave with an understanding of the current trends in biologics and biosimilars and how these trends will shape future opportunities."

  Presentation topics include:    --  What Opportunity Remains for Emerging and Novel Immune-Targeted Agents       in a TNF-Dominated World?   --  Processes and Paradigms: Which Companies Can Actually Produce       Biosimilars and How?   --  Monoclonal Antibodies and the Transformation of the Oncology Landscape   --  First-Launch Small Molecule Therapies and Biologic Agents: Challenges       and Opportunities Facing Novel Types of Therapies Entering New Markets   --  Moving Beyond the Major Markets: Current and Future Prospects for       Biologics in the Emerging Markets  

For more information about registration and to view the meeting agenda, please visit: http://www.competitivelandscapeseries.com/biologics-and-biosimilars/.

Media Invitation

Members of the media interested in receiving an invitation to the Decision Resources' Competitive Landscape Seminar Series: Biologics and Biosimilars should contact Lisa Osgood at 781-296-2606 or by e-mail at losgood@hl-isy.com.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

  For more information, contact:    Decision Resources                   Decision Resources, Inc.   Lisa Osgood                          Christopher Comfort   781-296-2606                         781-296-2597   losgood@hl-isy.com                   ccomfort@dresources.com 

First Call Analyst:
FCMN Contact:

SOURCE: Decision Resources

CONTACT: Lisa Osgood, Decision Resources, +1-781-296-2606,
losgood@hl-isy.com; or Christopher Comfort, Decision Resources, Inc.,
+1-781-296-2597, ccomfort@dresources.com

U.S. Physicians Will Require Less Clinical Trial Data Than European Physicians Before They are Comfortable Prescribing Biosimilars

View Now